Search research articles
Contact Us
Filters
Showing results (81-90 of 94) with videos related to
Page
of 10
Sort By:
Hemasphere
|
November 20, 2025
Outcomes of tafasitamab and lenalidomide in large B-cell lymphoma based on prior CD19-directed CAR T exposure
Mwanasha H Merrill, Robert A Redd, Nicholas Lambert, et al.
Journal of Hematology & Oncology
|
March 18, 2025
Second primary malignancies following CAR T-cell therapy in patients with hematologic malignancies
Elvira Umyarova, Charles Pei, William Pellegrino, et al.
Haematologica
|
October 15, 2020
Transducin β-like protein 1 controls multiple oncogenic networks in diffuse large B-cell lymphoma
Youssef Youssef, Vrajesh Karkhanis, Wing Keung Chan, et al.
American Journal of Hematology
|
November 24, 2016
Diffuse large B-cell lymphoma with primary treatment failure: Ultra-high risk features and benchmarking for experimental therapies
Luciano J Costa, Kami Maddocks, Narendranath Epperla, et al.
Blood
|
January 28, 2016
Ibrutinib enhances chimeric antigen receptor T-cell engraftment and efficacy in leukemia
Joseph A Fraietta, Kyle A Beckwith, Prachi R Patel, et al.
Blood
|
July 27, 2013
Ibrutinib is an irreversible molecular inhibitor of ITK driving a Th1-selective pressure in T lymphocytes
Jason A Dubovsky, Kyle A Beckwith, Gayathri Natarajan, et al.
Blood Advances
|
April 12, 2024
Postinfusion PD-1+ CD8+ CAR T cells identify patients responsive to CD19 CAR T-cell therapy in non-Hodgkin lymphoma
Nathan Denlinger, No-Joon Song, Xiaoli Zhang, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology
|
April 19, 2017
BTK<sup>C481S</sup>-Mediated Resistance to Ibrutinib in Chronic Lymphocytic Leukemia
Jennifer A Woyach, Amy S Ruppert, Daphne Guinn, et al.
Blood Advances
|
September 13, 2021
Early relapse identifies MCL patients with inferior survival after intensive or less intensive frontline therapy
David A Bond, Jeffrey M Switchenko, Diego Villa, et al.
Journal of the National Comprehensive Cancer Network : JNCCN
|
April 7, 2022
NCCN Guidelines® Insights: Hodgkin Lymphoma, Version 2.2022
Richard T Hoppe, Ranjana H Advani, Weiyun Z Ai, et al.
Page
of 10
Search research articles
Search
Showing results (81-90 of 94) with videos related to
Sort By:
Page
of 10
Hemasphere
|
November 20, 2025
Outcomes of tafasitamab and lenalidomide in large B-cell lymphoma based on prior CD19-directed CAR T exposure
Mwanasha H Merrill, Robert A Redd, Nicholas Lambert, et al.
Journal of Hematology & Oncology
|
March 18, 2025
Second primary malignancies following CAR T-cell therapy in patients with hematologic malignancies
Elvira Umyarova, Charles Pei, William Pellegrino, et al.
Haematologica
|
October 15, 2020
Transducin β-like protein 1 controls multiple oncogenic networks in diffuse large B-cell lymphoma
Youssef Youssef, Vrajesh Karkhanis, Wing Keung Chan, et al.
American Journal of Hematology
|
November 24, 2016
Diffuse large B-cell lymphoma with primary treatment failure: Ultra-high risk features and benchmarking for experimental therapies
Luciano J Costa, Kami Maddocks, Narendranath Epperla, et al.
Blood
|
January 28, 2016
Ibrutinib enhances chimeric antigen receptor T-cell engraftment and efficacy in leukemia
Joseph A Fraietta, Kyle A Beckwith, Prachi R Patel, et al.
Blood
|
July 27, 2013
Ibrutinib is an irreversible molecular inhibitor of ITK driving a Th1-selective pressure in T lymphocytes
Jason A Dubovsky, Kyle A Beckwith, Gayathri Natarajan, et al.
Blood Advances
|
April 12, 2024
Postinfusion PD-1+ CD8+ CAR T cells identify patients responsive to CD19 CAR T-cell therapy in non-Hodgkin lymphoma
Nathan Denlinger, No-Joon Song, Xiaoli Zhang, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology
|
April 19, 2017
BTK<sup>C481S</sup>-Mediated Resistance to Ibrutinib in Chronic Lymphocytic Leukemia
Jennifer A Woyach, Amy S Ruppert, Daphne Guinn, et al.
Blood Advances
|
September 13, 2021
Early relapse identifies MCL patients with inferior survival after intensive or less intensive frontline therapy
David A Bond, Jeffrey M Switchenko, Diego Villa, et al.
Journal of the National Comprehensive Cancer Network : JNCCN
|
April 7, 2022
NCCN Guidelines® Insights: Hodgkin Lymphoma, Version 2.2022
Richard T Hoppe, Ranjana H Advani, Weiyun Z Ai, et al.
Page
of 10